Identification of a methyltransferase-related long noncoding RNA signature as a novel prognosis biomarker for lung adenocarcinoma
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Researchers developed a prognostic gene signature for lung adenocarcinoma (LUAD) using methyltransferase-related long non-coding RNAs (MeRlncRNAs). This signature predicts patient outcomes and reveals suppressed immune landscapes in high-risk LUAD groups.
Area Of Science
- Oncology
- Molecular Biology
- Bioinformatics
Background
- Lung adenocarcinoma (LUAD) is a leading cause of cancer mortality worldwide.
- Methyltransferase-related long non-coding RNAs (MeRlncRNAs) in LUAD remain understudied.
- Understanding MeRlncRNAs is crucial for improving LUAD prognosis.
Purpose Of The Study
- To establish a prognostic signature of MeRlncRNAs in LUAD.
- To investigate the relationship between MeRlncRNAs, risk scores, and immune infiltration in LUAD.
- To validate the prognostic value of the identified MeRlncRNA signature.
Main Methods
- Utilized univariate Cox and LASSO regression analyses on TCGA-LUAD and GSE30219 cohorts.
- Performed Gene Set Enrichment Analysis (GSEA) and single-sample GSEA (ssGSEA) for pathway and immune infiltration analysis.
- Validated prognostic lncRNA expression using Reverse Transcription quantitative PCR (RT-qPCR).
Main Results
- Identified 32 MeRlncRNAs, and developed a six-lncRNA prognostic signature for LUAD.
- The risk score derived from the signature independently predicted prognosis and correlated with immune-related pathways.
- High-risk LUAD groups exhibited suppressed immune landscapes, suggesting a link to poorer outcomes.
- Constructed a regulatory network of prognostic lncRNAs, miRNAs, and mRNAs.
- RT-qPCR confirmed the expression patterns of prognostic lncRNAs.
Conclusions
- The developed MeRlncRNA-based prognostic gene signature offers a comprehensive tool for predicting LUAD patient prognosis.
- This signature highlights the role of MeRlncRNAs in LUAD progression and immune evasion.
- Further research into MeRlncRNAs could lead to novel therapeutic strategies for LUAD.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...